Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01173601 · ClinicalTrials.gov registry record · Phase 3
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,416
- Enrollment target
NCT01173601 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,416 participants.
The verdict
NCT01173601, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,416 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess whether at least 1 dose of LY2216684 (12 milligrams \[mg\] or 18 mg once daily) is superior to placebo once daily in the adjunctive treatment of participants with major depressive disorder (MDD) who were identified as partial responders to an adequate course of treatment with a selective serotonin reuptake inhibitor (SSRI) during an 8-week, double-blind, acute adjunctive treatment phase.
Interventions
- DRUG Placebo
- DRUG LY2216684
- DRUG SSRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,416 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01173601
The ClinicalTrials.gov registry entry for NCT01173601 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,416 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01173601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01173601 about?
NCT01173601 is a clinical study titled "A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder". The primary purpose of this study is to assess whether at least 1 dose of LY2216684 (12 milligrams \[mg\] or 18 mg once daily) is superior to placebo once daily in the adjunctive treatment of participants with major depressive disorder (MDD) who were identified as partial responders to an adequate c...
What is the current status of trial NCT01173601?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,416 participants. The study started on 2010-11. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01173601?
The interventions under investigation include: Placebo (DRUG), LY2216684 (DRUG), SSRI (DRUG).
Who is sponsoring clinical trial NCT01173601?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.